Non-recombinant coagulation factors refer to coagulation factors synthesized by the human body itself, which are different from coagulation factors synthesized through genetic recombination technology (recombinant coagulation factors). These coagulation factors are synthesized by the liver and other tissues of the human body under normal circumstances and play an important role in the coagulation process, helping to stop bleeding and maintain blood coagulation balance. Non-recombinant clotting factors are usually obtained from blood donations from healthy people.
The global Non-recombinant Coagulation Factors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Non-recombinant Coagulation Factors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Non-recombinant Coagulation Factors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Non-recombinant Coagulation Factors include Takeda Pharmaceutical, Instituto Grifols SA, CSL Behring LLC, KM Biologics KK, Baxter Healthcare Corp., Sanquin, Johnson & Johnson, Octapharma AG and Bio Products Laboratory Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Non-recombinant Coagulation Factors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-recombinant Coagulation Factors.
Report Scope
The Non-recombinant Coagulation Factors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-recombinant Coagulation Factors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-recombinant Coagulation Factors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda Pharmaceutical
Instituto Grifols SA
CSL Behring LLC
KM Biologics KK
Baxter Healthcare Corp.
Sanquin
Johnson & Johnson
Octapharma AG
Bio Products Laboratory Ltd.
Grifols Biologicals, Inc.
Pfizer Inc.
Intas Biopharmaceuticals Ltd.
Shandong Taibang Biological Products
Sinopharm Group Shanghai Blood Products
SHANGHAI RAAS
China Resources Boya Bio-Pharmaceutical
Chengdu Rongsheng Pharmaceuticals
Yuanda Shuyang Pharmaceutical
HUALAN BIO
Segment by Type
Coagulation Factor VIII
Human Fibrinogen
Others
Segment by Application
Hemophilia
Fibrinogen Deficiency
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Non-recombinant Coagulation Factors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Non-recombinant Coagulation Factors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Non-recombinant Coagulation Factors Market Overview
1.1 Product Overview and Scope of Non-recombinant Coagulation Factors
1.2 Non-recombinant Coagulation Factors Segment by Type
1.2.1 Global Non-recombinant Coagulation Factors Market Value Comparison by Type (2024-2030)
1.2.2 Coagulation Factor VIII
1.2.3 Human Fibrinogen
1.2.4 Others
1.3 Non-recombinant Coagulation Factors Segment by Application
1.3.1 Global Non-recombinant Coagulation Factors Market Value by Application: (2024-2030)
1.3.2 Hemophilia
1.3.3 Fibrinogen Deficiency
1.3.4 Other
1.4 Global Non-recombinant Coagulation Factors Market Size Estimates and Forecasts
1.4.1 Global Non-recombinant Coagulation Factors Revenue 2019-2030
1.4.2 Global Non-recombinant Coagulation Factors Sales 2019-2030
1.4.3 Global Non-recombinant Coagulation Factors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Non-recombinant Coagulation Factors Market Competition by Manufacturers
2.1 Global Non-recombinant Coagulation Factors Sales Market Share by Manufacturers (2019-2024)
2.2 Global Non-recombinant Coagulation Factors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Non-recombinant Coagulation Factors Average Price by Manufacturers (2019-2024)
2.4 Global Non-recombinant Coagulation Factors Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Non-recombinant Coagulation Factors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Non-recombinant Coagulation Factors, Product Type & Application
2.7 Non-recombinant Coagulation Factors Market Competitive Situation and Trends
2.7.1 Non-recombinant Coagulation Factors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Non-recombinant Coagulation Factors Players Market Share by Revenue
2.7.3 Global Non-recombinant Coagulation Factors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Non-recombinant Coagulation Factors Retrospective Market Scenario by Region
3.1 Global Non-recombinant Coagulation Factors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Non-recombinant Coagulation Factors Global Non-recombinant Coagulation Factors Sales by Region: 2019-2030
3.2.1 Global Non-recombinant Coagulation Factors Sales by Region: 2019-2024
3.2.2 Global Non-recombinant Coagulation Factors Sales by Region: 2025-2030
3.3 Global Non-recombinant Coagulation Factors Global Non-recombinant Coagulation Factors Revenue by Region: 2019-2030
3.3.1 Global Non-recombinant Coagulation Factors Revenue by Region: 2019-2024
3.3.2 Global Non-recombinant Coagulation Factors Revenue by Region: 2025-2030
3.4 North America Non-recombinant Coagulation Factors Market Facts & Figures by Country
3.4.1 North America Non-recombinant Coagulation Factors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Non-recombinant Coagulation Factors Sales by Country (2019-2030)
3.4.3 North America Non-recombinant Coagulation Factors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Non-recombinant Coagulation Factors Market Facts & Figures by Country
3.5.1 Europe Non-recombinant Coagulation Factors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Non-recombinant Coagulation Factors Sales by Country (2019-2030)
3.5.3 Europe Non-recombinant Coagulation Factors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Non-recombinant Coagulation Factors Market Facts & Figures by Country
3.6.1 Asia Pacific Non-recombinant Coagulation Factors Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Non-recombinant Coagulation Factors Sales by Country (2019-2030)
3.6.3 Asia Pacific Non-recombinant Coagulation Factors Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Non-recombinant Coagulation Factors Market Facts & Figures by Country
3.7.1 Latin America Non-recombinant Coagulation Factors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Non-recombinant Coagulation Factors Sales by Country (2019-2030)
3.7.3 Latin America Non-recombinant Coagulation Factors Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Non-recombinant Coagulation Factors Market Facts & Figures by Country
3.8.1 Middle East and Africa Non-recombinant Coagulation Factors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Non-recombinant Coagulation Factors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Non-recombinant Coagulation Factors Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Non-recombinant Coagulation Factors Sales by Type (2019-2030)
4.1.1 Global Non-recombinant Coagulation Factors Sales by Type (2019-2024)
4.1.2 Global Non-recombinant Coagulation Factors Sales by Type (2025-2030)
4.1.3 Global Non-recombinant Coagulation Factors Sales Market Share by Type (2019-2030)
4.2 Global Non-recombinant Coagulation Factors Revenue by Type (2019-2030)
4.2.1 Global Non-recombinant Coagulation Factors Revenue by Type (2019-2024)
4.2.2 Global Non-recombinant Coagulation Factors Revenue by Type (2025-2030)
4.2.3 Global Non-recombinant Coagulation Factors Revenue Market Share by Type (2019-2030)
4.3 Global Non-recombinant Coagulation Factors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Non-recombinant Coagulation Factors Sales by Application (2019-2030)
5.1.1 Global Non-recombinant Coagulation Factors Sales by Application (2019-2024)
5.1.2 Global Non-recombinant Coagulation Factors Sales by Application (2025-2030)
5.1.3 Global Non-recombinant Coagulation Factors Sales Market Share by Application (2019-2030)
5.2 Global Non-recombinant Coagulation Factors Revenue by Application (2019-2030)
5.2.1 Global Non-recombinant Coagulation Factors Revenue by Application (2019-2024)
5.2.2 Global Non-recombinant Coagulation Factors Revenue by Application (2025-2030)
5.2.3 Global Non-recombinant Coagulation Factors Revenue Market Share by Application (2019-2030)
5.3 Global Non-recombinant Coagulation Factors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda Pharmaceutical
6.1.1 Takeda Pharmaceutical Corporation Information
6.1.2 Takeda Pharmaceutical Description and Business Overview
6.1.3 Takeda Pharmaceutical Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Pharmaceutical Non-recombinant Coagulation Factors Product Portfolio
6.1.5 Takeda Pharmaceutical Recent Developments/Updates
6.2 Instituto Grifols SA
6.2.1 Instituto Grifols SA Corporation Information
6.2.2 Instituto Grifols SA Description and Business Overview
6.2.3 Instituto Grifols SA Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Instituto Grifols SA Non-recombinant Coagulation Factors Product Portfolio
6.2.5 Instituto Grifols SA Recent Developments/Updates
6.3 CSL Behring LLC
6.3.1 CSL Behring LLC Corporation Information
6.3.2 CSL Behring LLC Description and Business Overview
6.3.3 CSL Behring LLC Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CSL Behring LLC Non-recombinant Coagulation Factors Product Portfolio
6.3.5 CSL Behring LLC Recent Developments/Updates
6.4 KM Biologics KK
6.4.1 KM Biologics KK Corporation Information
6.4.2 KM Biologics KK Description and Business Overview
6.4.3 KM Biologics KK Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 KM Biologics KK Non-recombinant Coagulation Factors Product Portfolio
6.4.5 KM Biologics KK Recent Developments/Updates
6.5 Baxter Healthcare Corp.
6.5.1 Baxter Healthcare Corp. Corporation Information
6.5.2 Baxter Healthcare Corp. Description and Business Overview
6.5.3 Baxter Healthcare Corp. Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Baxter Healthcare Corp. Non-recombinant Coagulation Factors Product Portfolio
6.5.5 Baxter Healthcare Corp. Recent Developments/Updates
6.6 Sanquin
6.6.1 Sanquin Corporation Information
6.6.2 Sanquin Description and Business Overview
6.6.3 Sanquin Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanquin Non-recombinant Coagulation Factors Product Portfolio
6.6.5 Sanquin Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Johnson & Johnson Non-recombinant Coagulation Factors Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Octapharma AG
6.8.1 Octapharma AG Corporation Information
6.8.2 Octapharma AG Description and Business Overview
6.8.3 Octapharma AG Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Octapharma AG Non-recombinant Coagulation Factors Product Portfolio
6.8.5 Octapharma AG Recent Developments/Updates
6.9 Bio Products Laboratory Ltd.
6.9.1 Bio Products Laboratory Ltd. Corporation Information
6.9.2 Bio Products Laboratory Ltd. Description and Business Overview
6.9.3 Bio Products Laboratory Ltd. Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bio Products Laboratory Ltd. Non-recombinant Coagulation Factors Product Portfolio
6.9.5 Bio Products Laboratory Ltd. Recent Developments/Updates
6.10 Grifols Biologicals, Inc.
6.10.1 Grifols Biologicals, Inc. Corporation Information
6.10.2 Grifols Biologicals, Inc. Description and Business Overview
6.10.3 Grifols Biologicals, Inc. Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Grifols Biologicals, Inc. Non-recombinant Coagulation Factors Product Portfolio
6.10.5 Grifols Biologicals, Inc. Recent Developments/Updates
6.11 Pfizer Inc.
6.11.1 Pfizer Inc. Corporation Information
6.11.2 Pfizer Inc. Non-recombinant Coagulation Factors Description and Business Overview
6.11.3 Pfizer Inc. Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Pfizer Inc. Non-recombinant Coagulation Factors Product Portfolio
6.11.5 Pfizer Inc. Recent Developments/Updates
6.12 Intas Biopharmaceuticals Ltd.
6.12.1 Intas Biopharmaceuticals Ltd. Corporation Information
6.12.2 Intas Biopharmaceuticals Ltd. Non-recombinant Coagulation Factors Description and Business Overview
6.12.3 Intas Biopharmaceuticals Ltd. Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Intas Biopharmaceuticals Ltd. Non-recombinant Coagulation Factors Product Portfolio
6.12.5 Intas Biopharmaceuticals Ltd. Recent Developments/Updates
6.13 Shandong Taibang Biological Products
6.13.1 Shandong Taibang Biological Products Corporation Information
6.13.2 Shandong Taibang Biological Products Non-recombinant Coagulation Factors Description and Business Overview
6.13.3 Shandong Taibang Biological Products Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Shandong Taibang Biological Products Non-recombinant Coagulation Factors Product Portfolio
6.13.5 Shandong Taibang Biological Products Recent Developments/Updates
6.14 Sinopharm Group Shanghai Blood Products
6.14.1 Sinopharm Group Shanghai Blood Products Corporation Information
6.14.2 Sinopharm Group Shanghai Blood Products Non-recombinant Coagulation Factors Description and Business Overview
6.14.3 Sinopharm Group Shanghai Blood Products Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Sinopharm Group Shanghai Blood Products Non-recombinant Coagulation Factors Product Portfolio
6.14.5 Sinopharm Group Shanghai Blood Products Recent Developments/Updates
6.15 SHANGHAI RAAS
6.15.1 SHANGHAI RAAS Corporation Information
6.15.2 SHANGHAI RAAS Non-recombinant Coagulation Factors Description and Business Overview
6.15.3 SHANGHAI RAAS Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.15.4 SHANGHAI RAAS Non-recombinant Coagulation Factors Product Portfolio
6.15.5 SHANGHAI RAAS Recent Developments/Updates
6.16 China Resources Boya Bio-Pharmaceutical
6.16.1 China Resources Boya Bio-Pharmaceutical Corporation Information
6.16.2 China Resources Boya Bio-Pharmaceutical Non-recombinant Coagulation Factors Description and Business Overview
6.16.3 China Resources Boya Bio-Pharmaceutical Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.16.4 China Resources Boya Bio-Pharmaceutical Non-recombinant Coagulation Factors Product Portfolio
6.16.5 China Resources Boya Bio-Pharmaceutical Recent Developments/Updates
6.17 Chengdu Rongsheng Pharmaceuticals
6.17.1 Chengdu Rongsheng Pharmaceuticals Corporation Information
6.17.2 Chengdu Rongsheng Pharmaceuticals Non-recombinant Coagulation Factors Description and Business Overview
6.17.3 Chengdu Rongsheng Pharmaceuticals Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Chengdu Rongsheng Pharmaceuticals Non-recombinant Coagulation Factors Product Portfolio
6.17.5 Chengdu Rongsheng Pharmaceuticals Recent Developments/Updates
6.18 Yuanda Shuyang Pharmaceutical
6.18.1 Yuanda Shuyang Pharmaceutical Corporation Information
6.18.2 Yuanda Shuyang Pharmaceutical Non-recombinant Coagulation Factors Description and Business Overview
6.18.3 Yuanda Shuyang Pharmaceutical Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Yuanda Shuyang Pharmaceutical Non-recombinant Coagulation Factors Product Portfolio
6.18.5 Yuanda Shuyang Pharmaceutical Recent Developments/Updates
6.19 HUALAN BIO
6.19.1 HUALAN BIO Corporation Information
6.19.2 HUALAN BIO Non-recombinant Coagulation Factors Description and Business Overview
6.19.3 HUALAN BIO Non-recombinant Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
6.19.4 HUALAN BIO Non-recombinant Coagulation Factors Product Portfolio
6.19.5 HUALAN BIO Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Non-recombinant Coagulation Factors Industry Chain Analysis
7.2 Non-recombinant Coagulation Factors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Non-recombinant Coagulation Factors Production Mode & Process
7.4 Non-recombinant Coagulation Factors Sales and Marketing
7.4.1 Non-recombinant Coagulation Factors Sales Channels
7.4.2 Non-recombinant Coagulation Factors Distributors
7.5 Non-recombinant Coagulation Factors Customers
8 Non-recombinant Coagulation Factors Market Dynamics
8.1 Non-recombinant Coagulation Factors Industry Trends
8.2 Non-recombinant Coagulation Factors Market Drivers
8.3 Non-recombinant Coagulation Factors Market Challenges
8.4 Non-recombinant Coagulation Factors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Takeda Pharmaceutical
Instituto Grifols SA
CSL Behring LLC
KM Biologics KK
Baxter Healthcare Corp.
Sanquin
Johnson & Johnson
Octapharma AG
Bio Products Laboratory Ltd.
Grifols Biologicals, Inc.
Pfizer Inc.
Intas Biopharmaceuticals Ltd.
Shandong Taibang Biological Products
Sinopharm Group Shanghai Blood Products
SHANGHAI RAAS
China Resources Boya Bio-Pharmaceutical
Chengdu Rongsheng Pharmaceuticals
Yuanda Shuyang Pharmaceutical
HUALAN BIO
听
听
*If Applicable.